Stay updated on Pembrolizumab in Recurrent Gastric Cancer Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab in Recurrent Gastric Cancer Clinical Trial page.

Latest updates to the Pembrolizumab in Recurrent Gastric Cancer Clinical Trial page
- Check7 days agoChange DetectedThe web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content.SummaryDifference0.1%
- Check14 days agoChange DetectedThe web page has been updated to include new drug information for Pembrolizumab, Cisplatin, and Fluorouracil, as well as recent research articles related to stomach cancer. Additionally, the facility name and location have been added, while some previous location details and cancer-related terms have been removed.SummaryDifference7%
- Check21 days agoNo Change Detected
- Check28 days agoChange DetectedThe web page has been updated from version 2.16.11 to version 2.16.12.SummaryDifference0.1%
- Check35 days agoChange DetectedThe web page has been updated from version v2.16.10 to v2.16.11.SummaryDifference0.1%
- Check43 days agoChange DetectedThe web page has been updated to version 2.16.10, and a previous service alert regarding planned maintenance has been removed.SummaryDifference0.7%
- Check50 days agoChange DetectedThe page has been updated to reflect a new version, changing from Revision v2.16.6 to v2.16.8, and includes a new section on HHS Vulnerability Disclosure.SummaryDifference0.1%
Stay in the know with updates to Pembrolizumab in Recurrent Gastric Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in Recurrent Gastric Cancer Clinical Trial page.